These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 26827663)

  • 1. Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice.
    Rappazzo CG; Watkins HC; Guarino CM; Chau A; Lopez JL; DeLisa MP; Leifer CA; Whittaker GR; Putnam D
    Vaccine; 2016 Mar; 34(10):1252-8. PubMed ID: 26827663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
    Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
    Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice.
    Dabaghian M; Latifi AM; Tebianian M; Dabaghian F; Ebrahimi SM
    Antiviral Res; 2015 Aug; 120():23-31. PubMed ID: 25989418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
    Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
    Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safe Recombinant Outer Membrane Vesicles that Display M2e Elicit Heterologous Influenza Protection.
    Watkins HC; Rappazzo CG; Higgins JS; Sun X; Brock N; Chau A; Misra A; Cannizzo JPB; King MR; Maines TR; Leifer CA; Whittaker GR; DeLisa MP; Putnam D
    Mol Ther; 2017 Apr; 25(4):989-1002. PubMed ID: 28215994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
    Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
    Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.
    Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D
    Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection.
    Guo Y; He L; Song N; Li P; Sun S; Zhao G; Tai W; Jiang S; Du L; Zhou Y
    Microbes Infect; 2017 Dec; 19(12):641-647. PubMed ID: 28903071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single dose and long lasting vaccine against pandemic influenza through the controlled release of a heterospecies tandem M2 sequence embedded within detoxified bacterial outer membrane vesicles.
    Watkins HC; Pagan CL; Childs HR; Posada S; Chau A; Rios J; Guarino C; DeLisa MP; Whittaker GR; Putnam D
    Vaccine; 2017 Sep; 35(40):5373-5380. PubMed ID: 28866291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.
    Kim EH; Park HJ; Han GY; Song MK; Pereboev A; Hong JS; Chang J; Byun YH; Seong BL; Nguyen HH
    J Virol; 2014 Sep; 88(17):9693-703. PubMed ID: 24920793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
    Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
    PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
    Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
    J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection.
    Tao W; Gill HS
    Vaccine; 2015 May; 33(20):2307-15. PubMed ID: 25842219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.
    Wang W; Huang B; Wang X; Tan W; Ruan L
    Virol Sin; 2019 Oct; 34(5):583-591. PubMed ID: 31240620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].
    Stepanova LA; Kovaleva AA; Potapchuk MV; Korotkov AV; Kupriianov VV; Blokhina EA; Kotliarov RIu; Tsybalova LM
    Vopr Virusol; 2013; 58(3):21-5. PubMed ID: 24006628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge.
    Ma JH; Yang FR; Yu H; Zhou YJ; Li GX; Huang M; Wen F; Tong G
    Virol J; 2013 Jul; 10():227. PubMed ID: 23834899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
    Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
    Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice.
    Zhang J; Fan HY; Zhang Z; Zhang J; Zhang J; Huang JN; Ye Y; Liao M
    Vaccine; 2016 Jan; 34(5):622-629. PubMed ID: 26724200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.
    El Bakkouri K; Descamps F; De Filette M; Smet A; Festjens E; Birkett A; Van Rooijen N; Verbeek S; Fiers W; Saelens X
    J Immunol; 2011 Jan; 186(2):1022-31. PubMed ID: 21169548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine.
    Adler-Moore J; Munoz M; Kim H; Romero J; Tumpey T; Zeng H; Petro C; Ernst W; Kosina S; Jimenez G; Fujii G
    Vaccine; 2011 Jun; 29(27):4460-8. PubMed ID: 21545821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.